Intranasal amyloid-beta delivery creates a non-transgenic Alzheimer's model that may speed drug development | Research

The takeaway

Repeated intranasal delivery of Aβ1-42 peptide creates a non-transgenic animal model of Alzheimer's disease that replicates disease pathology more accurately than existing models, potentially accelerating therapeutic development.

Non-transgenic AD model
Intranasal Aβ1-42 delivery replicates Alzheimer's pathology without genetic manipulation, potentially improving preclinical drug development accuracy

What the researchers found

Intranasal Aβ1-42 induces AD-like pathology non-transgenically. Advantages: more accurate disease progression, no genetic manipulation. Challenges: dose standardization, timeline optimization. Potential to improve preclinical drug testing.

Why it matters

AD drug development has an extremely high failure rate partly due to inadequate animal models. A non-transgenic model that better replicates human disease could improve the predictive value of preclinical studies and accelerate therapeutic discovery.

How the study worked

Review of preclinical studies using intranasal amyloid-beta animal models of AD.

What this study cannot tell us

Review of developing model—standardization incomplete. Limited validation across laboratories. Does not replicate all AD features (e.g., tau pathology). Duration needed for full pathology development unclear.

How to read the evidence

Review of preclinical model development. Promising approach but still being standardized.

When this study was published

Published in 2025.

The bigger picture

Better animal models are essential for the AD drug pipeline. The intranasal amyloid approach bridges the gap between simple transgenic models and human disease complexity.

Questions still open

Can this model replicate tau pathology alongside amyloid?
What is the optimal Aβ1-42 dose and schedule for consistent pathology?
Will drugs effective in this model translate better to human trials?

Common questions

What is amyloid-beta and why is it important?

Amyloid-beta 1-42 (Aβ1-42) is a protein fragment that clumps together in the brains of Alzheimer's patients, forming plaques that damage neurons. Delivering this peptide intranasally to animals creates brain pathology that resembles human Alzheimer's, providing a better model for testing new drugs.

Why do we need better Alzheimer's models?

Most Alzheimer's drugs that work in current animal models fail in human trials—a 99% failure rate. This is partly because transgenic mouse models do not accurately replicate how Alzheimer's develops in humans. A more realistic model could help identify drugs that actually work in people.

Read the original research

Intranasal amyloid model of Alzheimer's disease - potential opportunities and challenges.

Pharmacological reports : PR, 77(2), 425-433

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Rakesh Kumar. (2025). Intranasal amyloid model of Alzheimer's disease - potential opportunities and challenges.. Pharmacological reports : PR, 77(2), 425-433. https://doi.org/10.1007/s43440-024-00692-4